


# Call for drug discovery and antibody targets

Find out if your  
research has the  
potential to become  
a small molecule  
drug project or  
therapeutic  
antibody




# Call for drug discovery and antibody targets

No matter what stage your research is at please submit your target for consideration in our small molecule drug discovery programmes or for our external therapeutic antibody development programmes.

MRC Technology's Centre for Therapeutics Discovery offers resources and expertise in drug discovery and antibody humanization including:

- **Provision of tool compounds and reagents/ability to raise antibodies against your target, for further target validation and characterisation studies**
- ***In silico* screening and compound design**
- **Access to medicinal chemistry, screening technologies and ADMET**
- **Design and development of therapeutic antibodies for the pharma/biotech industry**
- **Working with scientists with over 20 years in successfully humanizing antibodies**
- **Strong links to industry**
- **Potential access to funding**
- **Income generated from any programmes shared with your organisation**
- **Ability to develop novel drugs/antibody based drugs in areas of serious unmet need**

## Our drug discovery process



apply online at [callfortargets.org](http://callfortargets.org)




# Translating your targets into small molecule drugs

For small molecule drug discovery programmes we develop assays, conduct screening campaigns and engage in medicinal chemistry programmes. We collaborate with MRC, non-MRC scientists and clinicians, many of whom are world leaders in their fields. Our medicinal chemistry and biology teams have more than 100 people years of pharmaceutical company experience. We can deliver potent and selective lead compounds with efficacy in relevant disease models.

We use state of the art computational and medicinal chemistry to produce 'drug-like' molecules with the potential to become therapies. Promising molecules and antibodies will be taken down the path to clinical application by a partnership between the CTD, MRC, academic and other scientists and industry.

ctd@tech.mrc.ac.uk  
www.mrc technology.org  
+44 (0)20 8906 7100

## Typical progression path



# We can deliver humanized antibodies in just 6 months

Our Therapeutic Antibody Group, with over 20 years of experience working with both industry and academic groups, uses its substantial antibody engineering know-how to target major life threatening and debilitating diseases.

Antibody humanization is a rapid and reliable developmental process which offers: short clinical development times, high regulatory approval rates and better management of risk. Today, antibody humanization is a clinically validated technology with thirteen humanized antibodies already on the market (2 of which, Tysabri and Actemra, were humanized by our group) and another 100 or more in clinical trials.

Humanization remains the dominant technology currently being exploited by biopharmaceutical companies for the development of therapeutic antibodies.

To find out more about how you can work with our Centre for Therapeutics Discovery please contact:

ctd@tech.mrc.ac.uk  
www.mrctechnology.org  
+44 (0)20 8906 7100

## Our humanization process

### MONTHS 1-3

TAG scientists will not only clone & sequence the mouse variable region genes, enabling them to design the humanized antibody variants, but also make and test a chimeric version of the antibody.

If you do not have a mouse antibody against your novel target, we can generate mouse antibodies and help you to characterise and validate your target or its clinical potential.

PCR-clone & DNA sequence mouse variable region genes

Design, construct and test chimeric antibody

Design of the humanized antibody variable regions

### MONTHS 4-6

Scientists will construct and analyse several humanized antibody variants in an iterative process to generate the optimal humanized antibody against your target antigen:

Analysis & optimisation of the humanized antibody

Construct and analyse a panel of humanized antibody variants

Deliver your clinical candidate